, Author at UNION Therapeutics

UNION therapeutics announces full-year results for 2023

Hellerup, Denmark, February 7, 2024, – UNION therapeutics A/S (“UNION”), a privately held, clinical stage, pharmaceutical development company focused on immunology, announces full-year results for the period January 1 to […]

UNION therapeutics to present at the 42nd Annual J.P. Morgan Healthcare Conference

Hellerup, Denmark, January 5, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION […]

UNION therapeutics announces enrollment of the first patient in the UCORIS Phase 2 IIT study of orismilast in patients with ulcerative colitis

UCORIS is an investigator-initiated, Phase 2 study of orismilast for the treatment of moderate to severe ulcerative colitis (UC) UC is a chronic, inflammatory bowel disease with substantial unmet […]

UNION therapeutics A/S announces new paper on clinical potential of the emerging class of PDE4B/D inhibitors published in journal of Dermatology and Therapy

PDE4-inhibition is a well-established mechanism of action typically used for first line of treatment due to a well-documented safety and tolerability profile As the understanding of PDE4 inhibition has evolved, […]

UNION therapeutics A/S announces publication of results from the IASOS Phase 2b study of orismilast in psoriasis in Journal of the American Academy of Dermatology

In the Phase 2b study, orismilast significantly reduced Psoriasis Area and Severity Index (PASI) compared with placebo from baseline to week 16 39.5% to 49.0% of patients treated with orismilast […]

UNION therapeutics A/S completes patient enrollment for ADESOS Phase 2b study of orismilast in patients with atopic dermatitis

Topline results are expected in the first half of 2024 Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the developed world and a significant unmet […]

UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa

Study demonstrates clinically relevant improvements in patients with hidradenitis suppurativa (HS) receiving 16 weeks of treatment with oral orismilast Study supports the dose-finding results from the recent IASOS Phase 2b […]

Author: